Novartis | NOVN - Loan Capital

Stock Price
130.50
Daily Change
2.40 1.87%
Monthly
14.27%
Yearly
33.63%
Q1 Forecast
123.39

Novartis reported $24.24B in Loan Capital for its fiscal quarter ending in September of 2025.





Loan Capital Change Date
AbbVie USD 62.97B 12M Sep/2025
Alcon AG USD 4.59B 73M Sep/2025
Almirall EUR 324.81M 61.32M Dec/2025
Amgen USD 50B 2.43B Dec/2025
AstraZeneca USD 26.14B 19.58B Dec/2025
Autolus Therapeutics Ltd USD 244.63M 8.81M Jun/2025
Bayer EUR 32.71B 1B Sep/2025
Biogen USD 6.29B 1.4M Sep/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Fresenius EUR 10.8B 1.49B Sep/2025
Fresenius Medical Care EUR 4.85B 4.49B Dec/2025
Galapagos EUR 5.76M 290K Sep/2025
Genmab DKK 126M 6M Sep/2025
Gilead Sciences USD 22.14B 5M Sep/2025
GlaxoSmithKline GBP 14.71B 186M Dec/2025
GRIFOLS EUR 9.09B 1.64B Sep/2025
Hikma Pharmaceutical USD 798M 191M Jun/2025
J&J USD 39.44B 30M Dec/2025
Lonza CHF 4.24B 602M Dec/2024
Merck EUR 10.45B 4.15B Sep/2025
Merck USD 39.97B 6B Sep/2025
Novartis USD 24.24B 174M Sep/2025
Novartis USD 24.24B 174M Sep/2025
Novo Nordisk DKK 118.94B 29.76B Dec/2025
Orion EUR 129.6M 6.4M Sep/2025
Pfizer USD 57.41B 93M Sep/2025
Philips EUR 6.93B 303M Dec/2025
Recordati EUR 2.18B 89.51M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Roche Holding CHF 27.43B 966M Dec/2025
Sanofi EUR 15.72B 2.45B Dec/2025
UCB EUR 2.82B 146M Jun/2025